Skip to main content
OpenTrials
Completed

NCT Number: NCT06874361

Cooling to Alleviate Migraine #3

This is a prospective, double-blind, sham-controlled, randomized, decentralized trial. This study aims to assess the safety and efficacy of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home setting.

Adults aged 18 years to 70 years old with a diagnosis of migraine (with or without aura) for at least one year will be recruited for this study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

SPRIM Pro

Indian Harbour Beach, Florida, 32937, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age of 18 to 70 years, inclusive, of either sex at birth.
  • Lives in the contiguous United States.
  • Self-reported to be able to read and understand English sufficiently to provide electronic Informed Consent.
  • Diagnosis of migraine with or without aura for at least 1 year.
  • Individual experiences 2 to 8 migraine attacks per month documented via migraine eDiary during screening.
  • Migraine onset before 50 years of age, self-reported during screening.
  • Migraine preventive medication unchanged for 4 weeks prior to study enrollment.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Individuals that own a functioning smartphone device, internet connection (Wi-Fi or data plan) and are willing to download the study app.

Exclusion criteria

  • Participant has difficulty distinguishing his or her migraine attacks from other types of headaches such as tension, exertion, cluster, hormonal or sinus headaches.
  • Participant has 15 or more headache days per month reported via migraine eDiary and during screening.
  • Participant using any opioid medication at the time of screening.
  • Participant has received Botox treatment, barbiturates, SPG block, nerve blocks or trigger point injections in the head or neck within the last 4 weeks of screening.
  • Participant lives at an altitude of 2000 meters or more above sea level.
  • Self-reported intolerance to intranasal therapy.
  • Self-reported recurrent epistaxis or chronic rhinosinusitis.
  • Self-reported sinus or intranasal surgery within the last 4 months of screening.
  • Self-reported history of 'complicated migraine or headaches' (i.e., hemiplegic migraine, ophthalmoplegic migraine, migrainous infarction, basilar migraine, post-traumatic headaches, post-concussion syndrome).
  • Known or suspected pregnancy as self-reported by the prospective participant at the time of screening.
  • Prospective participant unable to fully understand the consent process and provide informed consent due to either language barriers or mental capacity.
  • Self-reported diagnosis of alcohol or substance abuse disorder at the time of screening.
  • Participant with active chronic pain syndromes, such as fibromyalgia, chronic pelvic pain, or Complex Regional Pain Syndrome (CRPS); or other pain syndrome like trigeminal neuralgia.
  • Participant with severe uncontrolled psychiatric conditions or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments.
  • Failure to adhere to or inability to complete Study App inputs and onboarding activities during the screening period. Participants who are not adherent during the screening period are not eligible for study entry.
  • Participation in a previous clinical study with the Mi-Helper device.
  • Participation in a migraine study or any other interventional clinical study within the3 months prior to screening.
  • Participant has an uncontrolled medical issue at the time of screening.
  • Any condition for which transnasal air flow would be contraindicated, as determined by the Principal Investigator (PI).

Treatment and study plan

Mi-Helper

Device

The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.

Primary outcomes

  1. Pain Freedom at 2 Hours Post Treatment

    Time frame: 2 hours

    Proportion of participants with a change in headache severity from mild/moderate/severe pain at baseline to no pain at 2 hours after treatment completion (if rescue medication was not used)

Secondary outcomes

  1. Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post Treatment

    Time frame: 2 hours

    Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none at 2 hours post treatment completion.

  2. Sustained Pain Freedom at 24 Hours Post Treatment

    Time frame: 2-24 Hours

    Proportion of participants with pain freedom with no administration of rescue medication and with no recurrence of a mild/moderate/severe headache

  3. Pain Relief at 2 Hours Post Treatment

    Time frame: 2 hours

    Proportion of participants with a change in headache severity from severe or moderate pain at baseline to mild or no pain at 2 hours post treatment completion, or from mild pain at baseline to no pain no pain at 2 hours after treatment completion (if rescue medication was not used)

  4. Participants' Global Impression of Acute Treatment Effect

    Time frame: 24 Hours

    Measured by the Patient Global Impression of Change (PGIC), on which participants use a 7-point scale, where 1=very much improved to 7=very much worse. Scores of 1 or 2 will be considered successes.

Other outcomes

  1. Rescue Medication Use

    Time frame: 2 Hours

    Use of rescue medication before 2 hours post treatment completion.

  2. Pain Freedom Immediately Post Treatment

    Time frame: 0 Hours

    Proportion of participants with a change in headache severity from mild/moderate/severe pain at baseline to no pain at 2 hours after treatment completion (if rescue medication was not used)

  3. Pain Relief Immediately Post Treatment

    Time frame: 0 minutes

    Proportion of participants with a change in headache severity from severe or moderate pain at baseline to mild or no pain at 0 hours post treatment completion, or from mild pain at baseline to no pain no pain at 0 hours after treatment completion (if rescue medication was not used)

  4. Sustained Pain Freedom at 48 Hours Post Treatment

    Time frame: 2 - 48 Hours

    Proportion of participants with pain freedom with no administration of rescue medication and with no recurrence of a mild/moderate/severe headache

  5. Freedom From Most Bothersome Symptom (MBS) at Immediately Post Treatment

    Time frame: 0 minutes

    Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none immediately post treatment completion.

  6. Relief From Most Bothersome Symptom (MBS) Immediately Post Treatment

    Time frame: 0 hours

    Proportion of participants with a change from severe or moderate symptom severity at baseline to the traditional 4-point Visual Rating Scalemild or none at 0 hours, or from mild symptom severity at baseline to none at 0 hours post treatment completion (based on the traditional 4-point Visual Rating Scale)

  7. Freedom From Nausea Immediately Post Treatment

    Time frame: 0 hours

    Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none immediately post treatment completion (based on the traditional 4-point Visual Rating Scale)

  8. Freedom From Photophobia Immediately Post Treatment

    Time frame: 0 Hours

    Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none ( immediately post treatment completion.

  9. Freedom From Phonophobia Immediately Post Treatment

    Time frame: 0 hours

    Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none immediately post treatment completion.

  10. Freedom From Nausea at 2 Hours Post Treatment

    Time frame: 2 Hours

    A reduction from mild, moderate or severe symptom severity at baseline to none at 2 hours post treatment completion.

  11. Freedom From Photophobia at 2 Hours Post Treatment

    Time frame: 2 Hours

    Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none at 2 hours post treatment completion.

  12. Freedom From Phonophobia at 2 Hours Post Treatment

    Time frame: 2 Hours

    Proportion of participants with a change from mild, moderate or severe symptom severity at baseline to none at 2 hours post treatment completion.

Sponsors and collaborators

Lead sponsor

Mi-Helper, Inc.

Industry

Registry information

Official study title

A Prospective, Double-blind, Sham-controlled, Randomized Clinical Trial to Assess the Safety and Efficacy of the Mi-Helper Device for Acute Treatment of Migraine in an At Home Setting.

Acronym: CALM3

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Mar 13, 2025
Registry last updated
Feb 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.